---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-077865"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2025-05-27T23:59:59+00:00"
generated_at: "2026-05-20T10:48:45.384405+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting

## Summary
- Elected Matthew W. Foehr (28.1M for, 16.2M withheld) and Charles A. Rowland, Jr. (33.0M for, 11.3M withheld) as Class I directors.
- Ratified CBIZ CPAs P.C. as independent auditor for FY2025: 75.2M for, 992K against, 473K abstentions.
- Advisory say-on-pay proposal approved: 29.3M for, 14.5M against, 506K abstentions, 32.4M broker non-votes.
- Meeting quorum of 76.7M shares (68.3% of 112.3M outstanding shares) represented.

## SEC filing metadata
- accession: 0000950170-25-077865
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2025-05-27T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017025077865/0000950170-25-077865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017025077865/vktx-20250520.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-077865
- JSON: https://secwatch.observer/filing/0000950170-25-077865.json
- Plain text: https://secwatch.observer/filing/0000950170-25-077865.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.